Category Archives: Drugs

Novartis’s challenge on validity of Indian patent laws was put down by Indian High Court

Swiss pharma giant, Novartis, faced another blow in India, when Chennai High Court rejected its writ petition challenging the validity of Indian Patent Laws. Novartis had sought to declare Section 3 (d) of the Indian Patents Act as substituted by Patents … Continue reading

Posted in Drugs, India, IP Systems, Litigation, Patent, TRIPS | Leave a comment

Indian firms and brazilian AIDS patients to be benefit from compulsory licensing

The Brazilian government’s decision to override the patent rights of Merck’s HIV/AIDS drug Stocrin (efavirenz) and buy reverse engineered generic versions of the drug at low cost has come as a boon for Indian pharmaceutical companies manufacturing generic versions of … Continue reading

Posted in Drugs, India, Patent, TRIPS, WTO | Leave a comment

US pushes bill to promote competitive presence of generic drug manft.

The bipartisan Preserve Access to Affordable Generics Act (S. 316) would prohibit brand-name drug companies from exploiting a loophole in the Hatch-Waxman Act to pay generic drug companies to delay entry of new generic medicines into the market. The bill … Continue reading

Posted in Drugs, USA | Leave a comment

Glaxo’s patent on AIDS drug opposed by INP+ in India

Glaxo's patent on AIDS drug opposed by INP+ in India The World Trade Review: "Intellectual Property Rights (TRIPs), 16-30 April 2006 Mumbai: People living with HIV/AIDS are taking on drug major GlaxoSmithKline's efforts to patent its AIDS-medicine Combivir in India. … Continue reading

Posted in Drugs, Patent | Leave a comment

TRIPS & Convention on Biological Diversity (CBD) Alaince worries Western Pharma/ Biotech Companies

TRIPS & Convention on Biological Diversity (CBD) Alaince worries Western Pharma/ Biotech Companies Tuesday, January 10, 2006 By Stephanie Weinberg U.S. biotech firms representing a variety of industries are working to ward off efforts by India, Brazil and other developing … Continue reading

Posted in Drugs, TRIPS | Leave a comment

US again threatns to suspend patent rights on health hazard grounds..

Apprehension about offering the stringent Product Patent protection to Pharma inventions during the TRIPs negotiations are turning the to be true. Even in developed world, companies holding the key patented medicine were reluctant to offer the medicines to the needy … Continue reading

Posted in Drugs, TRIPS, USA | Leave a comment

Anchen files ANDA for Wellbutrin XL (buproprion)

Anchen files ANDA for Wellbutrin XL (buproprion) Anchen files ANDA for Wellbutrin XL (buproprion) By Lawrence B. Ebert Taiwan-based generic company Anchen Pharmaceuticals has submitted an abbreviated new drug application (ANDA) to the FDA for Biovail’s Wellbutrin XL (once daily … Continue reading

Posted in Drugs, Patent, USA | Tagged , , , , , , | Leave a comment

REFUSING TO SUPPLY IN CHEAP JURISDICTIONS MAY BE OKAY, SAYS AG

IPKat – fishing for IP stories for YOU: “Friday, October 29, 2004 REFUSING TO SUPPLY IN CHEAP JURISDICTIONS MAY BE OKAY, SAYS AG Yesterday in Case C-53/03 Synetairismos Farmakopoion Aitolias & Akarnanias (Syfait) and Others v Glaxosmithkline AEVE Advocate General … Continue reading

Posted in Drugs, Litigation, Patent | Tagged , | Leave a comment

ANDA filing doesn’t constitute Willful patent infringement

“Glaxo Group Limited v. Apotex, Inc., 2004 U.S. App. LEXIS 15489 (Fed. Cir., July 27, 2004) Apotex, Inc. (‘Apotex’) appeals the judgment of the United States District Court for the Northern District of Illinois, which found that Apotex’s filing of … Continue reading

Posted in Drugs, Litigation, Patent, USA | Tagged , , , , , , | Leave a comment

WAR FOR DRUGS……..

Drug Wars: six lawyers discussing genrics Vs big Pharma drug war In our roundtable, pharma lawyers dissect the changes in Hatch-Waxman, the costs of patent litigation, and the blurring line between generic and branded drug companies. IP Law & Business/August … Continue reading

Posted in Drugs, Patent | Tagged , , , , | Leave a comment